A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Anne Blaes, MD,MS
- Phone Number: 612-625-9604
- Email: blaes004@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or above at the time of signing the informed consent form.
- Histologically proven diagnosis of stage I-III invasive breast cancer.
- Currently taking prescribed dose of an aromatase inhibitor (e.g., anastrazole, letrozole, exemestane) for at least 60 days with a plan to continue for at least 4 weeks after time of consent.
- Initiated AI therapy must have been within 48 months at time of consent.
- Experiencing AIMSS in hands and/or wrists for at least 4 weeks prior to time of consent.
- Patients must have reported a score of 4 or higher on at least one of the four M-SACRAH questions regarding pain and stiffness in hands and/or wrists over the past 7 days. Patients experiencing AIMSS symptoms in other joints are eligible, but must have pain in hands and/or wrists.
- Must be willing and able to comply with study visits and procedures.
- Must be willing to be registered in the Minnesota Medical Cannabis Program (MMCP).
- Must meet qualifications for the Minnesota Medical Cannabis
Program (MMCP). This includes:
- Must have a qualifying condition, as per MMCP requirements, that is certified by a Health Care Practitioner.
- Must be a Minnesota resident.
Exclusion Criteria:
- The patient is currently using or has used cannabinoids within 4 weeks of time of consent.
- Active skin lesions on hands/wrists that the investigator feels could impair absorption of cannabinoid cream or lead to increased toxicity (e.g., psoriasis, cellulitis, cutaneous lupus erythematosus, hand-foot syndrome).
- Plan to start or increase doses of other analgesics aimed at improving AIMSS symptoms (e.g., duloxetine, non-steroidal anti- inflammatories, acetaminophen, opioids). Of note, patients are eligible if they have remained on stable doses of AIMSS related medications for 4 weeks prior to time of consent and do not plan to escalate the dose.
- Current or planned initiation of acupuncture to arms, wrists or hands within study period.
- Any known or suspected hypersensitivity to topical cannabinoids.
- Any condition that the investigator believes would interfere with the ability to provide informed consent, comply with the study protocol, or would put the subject at undue risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Violet
Patients receiving CBD-dominant balm
|
product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar.
Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm.
Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar).
The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers.
After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
|
|
Experimental: Red Xs
Patients receiving THC-dominant balm
|
contains 375mg THC and less than 20mg CBD per 1.5 ounce jar.
Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm.
Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar).
The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers.
After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
subject recruitment rate
Time Frame: 4 weeks
|
percentage of participants actually recruited out of anticipated
|
4 weeks
|
|
subject retention rate
Time Frame: 4 weeks
|
percentage of participants who completed the study
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in Brief Pain Inventory Short Form (BPI-SF) scores
Time Frame: 2 weeks and 4 weeks
|
worst pain, average pain, pain interference with general activity minimum value is zero equals no pain and maximum value is 10 equals pain as bad as you can imagine and the higher the score the worse the outcome.
|
2 weeks and 4 weeks
|
|
tolerability of topical medical cannabis creams
Time Frame: 2 weeks and 4 weeks
|
documenting patient adherence to dosing protocol through a Patient Topical Cannabis Dosing Diary. This is a document where the patient records the date, time, to which hands the dose was applied and if the dose was missed. |
2 weeks and 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anne Blaes, MD,MS, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AIMSS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.